Altogether, these data demonstrate that MGL acts as a negative regulator in autoimmune-induced neuroinflammation, uncovering a novel clue for neuroprotective therapeutic strategies with relevance in MS clinical applications. Here, CLEC10A is linked to myeloid sarcoma.